FDA Goes After Supplement Manufacturers Making Health Claims

FDA Goes After Supplement Manufacturers Making Health Claims

The FDA appears to be taking a tougher stance on supplement manufacturers that make unsubstantiated claims that their products can treat or cure disease.

The FDA on Monday said it sent 17 warning or advisory letters to companies selling supplements that the firms touted treat Alzheimer’s disease. The agency said that the “products may be ineffective, unsafe and could prevent a person from seeking an appropriate diagnosis and treatment.”

Separately, FDA Commissioner Scott Gottlieb signaled that the agency would be taking steps to protect the public from potentially dangerous supplements, as well as seek to have more regulation over the industry. Unlike drugs, supplements don’t have to go through the same level of scrutiny before they hit the market.

This is thanks to the Dietary Supplement Health and Education Act (DSHEA) of 1994, which puts the onus the FDA to show a supplement is unsafe. And while the law requires that supplement manufacturers notify the FDA they are making a supplement, they don’t have to tell the agency what goes into it.

In a statement, Gottlieb said that the industry has grown exponentially since the DSHEA came out. In 1994, supplements were a $4 billion industry with about 4,000 products. Now, according to Gottlieb, it is worth about $40 billion and has as many as 80,000 products.

“I’m concerned that changes in the supplement market may have outpaced the evolution of our own policies and our capacity to manage emerging risks,” Gottlieb said. “To continue to fulfill our public health obligations we need to modernize and strengthen our overall approach to these products.”

He added he will start a “public dialogue” to see if changes to the DSHEA are necessary.


Jonathan Block

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Synthetic Red Blood Cells, NOAC’s for Atrial Fibrillation, Surgery to Ease Sciatica Pain

Synthetic Red Blood Cells, NOAC’s for Atrial Fibrillation, Surgery to Ease Sciatica Pain

Researchers have managed to create artificial red blood cells that can transport medication. Compared to the popular anticoagulant Warfarin, NOAC’s may be superior for treating atrial fibrillation patients with prior intracranial hemorrhage. Also, surgery may be the preferred choice for reducing leg pain in patients with sciatica.  Synthetic Red Blood…

FDA Recalls Metformin and NP Thyroid

FDA Recalls Metformin and NP Thyroid

The FDA has issued a recall of two drugs–NP Thyroid and Metformin–after testing revealed that they weren’t up to code. Read more below, and if you’re taking either medication, please be sure to contact your doctor for how to continue treatment responsibly.  NP Thyroid Recalled Thirteen lots of NP Thyroid,…

  • Advertisement